🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#GlomConHawaii 2025 🌴🌊 session: Post-market Evaluations, Registries, and RWE Studies Discussion on the importance and methodology of post-market evaluations, patient registries, and real-world evidence studies to assess long-term outcomes. Register here 👉

Our review on advances in the treatment of AAV is out now in NatRevRheumatol. It provides an update on currently used therapies and identified major innovations which will become relevant in the next couple of years! EUVAS nature.com/articles/s4158…

#ERA25 - Don't dream it's over! marcus_saemann Sara Helena Ksiazek & me are honored to host ERA - European Renal Association President Roser Torra NDT EiC Hans-Joachim Anders and #ERA26 Local President Dr Dr Kate Stevens💙 plus 7 Late-breaker PIs for our post-ERA webinar youtu.be/s-iglqVIp2s?si… via YouTube

Outstanding review that outlines evolving #ANCA #vasculitis treatments: from B-cell therapies (obinutuzumab, CAR-T) and T-cell therapies to new comers (T-cell engagers, alternative-pathway inhibitors, antifibrotics, ANCA–antigen blockers). A must read! nature.com/articles/s4158…

Pleasure was mine Milena Bond!

TMAs can be classified as primary or secondary based on whether #complement abnormalities are the primary cause, but now it seems as if complement activation can contribute to secondary TMAs as well. academic.oup.com/ndt/advance-ar… #aHUS #primaryTMA

Please vote for Jasper Callemeyn! No words are needed - he is amazing!

Congratulations to the NDT journals for a rising impact factor!

Registrations are open! Fees are low and scientific programme is rich! 🔥 💪🏻 Hands-on courses and KDIGO sessions! TürkNefrolojiDerneği Beatriz Fernandez Fernandez Serhan Tuğlular Marici Paola Romagnani Eleni Frangou Roser Torra Gregorio Romero-González Hans-Joachim Anders

2024 Nephrology Journal Impact Factors (JIF) were reported today. Remember this is a bibliometric measure & not a quality measure (how many times articles from 2022/2023 were cited in average during 2024)

Great presentation by Brendon Neuen here at the Korean Society of Nephrology meeting! Make sure to read this review published in NDT (academic.oup.com/ndt/article/40…)

Ein absolutes ‘Muss’! Freue mich darauf! Eine tolle Plattform für diese Diskussion und freue mich besonders auf Ruşen Timur Aksak

It was an honor to participate during the JSN-ERA symposium at the 68th Annual Meeting of the Japanese Society of Nephrology in Yokohama 🇯🇵 Returning to Europe feeling inspired by the vibrant Japanese community and their scientific contributions! ERA - European Renal Association Roser Torra

Current controversies in ANCA-associated vasculitis therapy: pulse steroids PEXIVAS reduced dose GC low-dose CYC+ritux PLEX ritux dosing (lovely table NatRevRheumatol from some great minds in AAV including Marta Casal Moura Andreas Kronbichler Benjamin Terrier Stephen McAdoo & many others)

12/n #ECNeph Int Society of Nephrology manjusha yadla Dilushi Wijayaratne Shubharthi Kar, MD, FISN A recent #CKJ publication : evaluation for routine cancer screening in PLA2R +ve PMN Check this infographic Our Pt : No weight loss , Xray : WNL , PSA : WNL USG abdomen : WNL PLA2R negative

24/n #ECNeph manjusha yadla Dilushi Wijayaratne Int Society of Nephrology Krithika Mohan Shubharthi Kar, MD, FISN When to suspect malignancy in GN academic.oup.com/ckj/article/18…

🦀🫘Cancer screening in Glomerular Disease academic.oup.com/ckj/article/18… CKJ

Malignancies and glomerulonephritis: ▫️Occult malignancies generally manifest within 1 year of initial GN diagnosis ▫️THSD7A and NELL-1 antibodies are detectable in ∼20%–30% of cases of malignancy-related MN ▫️Paraneoplastic GNs can be associated with all glomerular lesions

Malignancies and glomerulonephritis: when to suspect and when to screen? ca. 2025 from CKJ Andreas Kronbichler Annette Bruchfeld Dr Dr Kate Stevens💙 #Nephpearls 👉 pubmed.ncbi.nlm.nih.gov/40352576/

It was a pleasure to collaborate with Andreas Kronbichler and Astrid Weins on this article. We describe transformations in our understanding of podocytopathies, and novel treatment approaches in light of those advancements. journals.lww.com/co-nephrolhype…